Bibliographic Details
| Title: |
A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the LVUFT study. |
| Authors: |
Akio Saiura1 saiura-tky@umin.ac.jp, Junji Yamamoto2, Kiyoshi Hasegawa3, Masaru Oba3, Tadatoshi Takayama4, Shinichi Miyagawa5, Masayoshi Ijichi6, Masanori Teruya7, Fuyo Yoshimi8, Seiji Kawasaki9, Hiroto Koyama10, Masatoshi Makuuchi11, Norihiro Kokudo3 |
| Source: |
Drug Discoveries & Therapeutics. Feb2014, Vol. 8 Issue 1, p48-56. 9p. |
| Subject Terms: |
*URACIL, *FOLINIC acid, *HEPATECTOMY, *COLON cancer treatment, *ADJUVANT treatment of cancer, *RANDOMIZED controlled trials, *THERAPEUTICS |
| Abstract: |
The use of adjuvant systemic chemotherapy for resectable liver metastases from colorectal cancer (CRC) is controversial because no trial demonstrated its benefit. We conducted the phase III trial to evaluate UFT/leucovorin (LV) for colorectal liver metastases (CRLM). The primary endpoint has not been available until 2014, we first report the feasibility and safety data of UFT/LV arm. In this multicenter trial, patients who underwent curative resection of liver metastases from colorectal cancer were randomly assigned to receive surgery alone or surgery followed by adjuvant chemotherapy with UFT/LV. The primary endpoint was relapse-free survival. Secondary endpoints included overall survival and safety. A total of 180 patients were enrolled, 90 were randomly assigned to receive UFT/LV therapy. Eighty two of whom were included in safety analyses. In the UFT/LV group, the completion rate of UFT/LV was 54.9%, the relative dose intensity was 70.8% and grade 3 or higher adverse events occurred in 12.2% of the patients. Elevated bilirubin levels, decreased hemoglobin levels, elevated alanine aminotransferase levels, diarrhea, anorexia were common. Most other adverse events were grade 2 or lower and tolerable. In conclusions, UFT/LV is a safe regimen for postoperative adjuvant chemotherapy in patients who have undergone resection of liver metastases from colorectal cancer. Further studies are warranted to improve completion rate, but UFT/LV is found to be a promising treatment in this setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Drug Discoveries & Therapeutics is the property of International Advancement Center for Medicine & Health Research Co., Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
